Please Wait.....
Report
Lung Cancer Treatment Market (Treatment Type: Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
Market Report I 2023-01-20 I 213 Pages I Transparency Market Research
Lung Cancer Treatment Market - Scope of Report
TMR's report on the global lung cancer treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global lung cancer treatment market for the period 2017-2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global lung cancer treatment market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the lung cancer treatment market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global lung cancer treatment market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global lung cancer treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global lung cancer treatment market.
The report delves into the competitive landscape of the global lung cancer treatment market. Key players operating in the global lung cancer treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global lung cancer treatment market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market lung cancer treatment.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants' insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
- Industry Sources:
o WorldWideScience.org
o Elsevier, Inc.
o National Institutes of Health (NIH)
o PubMed
o NCBI
o Department of Health Care Service
- Trade Data Sources
o Trade Map
o UN Comtrade
o Trade Atlas
- Company Information
o OneSource Business Browser
o Hoover's
o Factiva
o Bloomberg
- Mergers & Acquisitions
o Thomson Mergers & Acquisitions
o MergerStat
o Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team's expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from "Secondary & Primary Sources" is cross-checked with "TMR Knowledge Repository", which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Lung Cancer Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Lung Cancer Treatment Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter's Five Forces Analysis
5. Key Insights
5.1. Lung Cancer Epidemiology
5.2. Pipeline Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Lung Cancer Treatment Market Analysis and Forecast, by Cancer Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Cancer Type, 2017-2031
6.3.1. NSCLC
6.3.2. SCLC
6.4. Market Attractiveness Analysis, by Cancer Type
7. Global Lung Cancer Treatment Market Analysis and Forecast, by Treatment Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Treatment Type, 2017-2031
7.3.1. Surgery
7.3.2. Radiation Therapy
7.3.3. Targeted Therapy
7.3.4. Immunotherapy
7.3.5. Chemotherapy
7.3.6. Others (palliative care)
7.4. Market Attractiveness Analysis, by Treatment Type
8. Global Lung Cancer Treatment Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017-2031
8.3.1. Hospitals
8.3.2. Cancer & Radiation Therapy Centers
8.3.3. Others (specialty clinics)
8.4. Market Attractiveness Analysis, by End-user
9. Global Lung Cancer Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Lung Cancer Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Cancer Type, 2017-2031
10.2.1. NSCLC
10.2.2. SCLC
10.3. Market Value Forecast, by Treatment Type, 2017-2031
10.3.1. Surgery
10.3.2. Radiation Therapy
10.3.3. Targeted Therapy
10.3.4. Immunotherapy
10.3.5. Chemotherapy
10.3.6. Others (palliative care)
10.4. Market Value Forecast, by End-user, 2017-2031
10.4.1. Hospitals
10.4.2. Cancer & Radiation Therapy Centers
10.4.3. Others (specialty clinics)
10.5. Market Value Forecast, by Country, 2017-2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Cancer Type
10.6.2. By Treatment Type
10.6.3. By End-user
10.6.4. By Country
11. Europe Lung Cancer Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Cancer Type, 2017-2031
11.2.1. NSCLC
11.2.2. SCLC
11.3. Market Value Forecast, by Treatment Type, 2017-2031
11.3.1. Surgery
11.3.2. Radiation Therapy
11.3.3. Targeted Therapy
11.3.4. Immunotherapy
11.3.5. Chemotherapy
11.3.6. Others (palliative care)
11.4. Market Value Forecast, by End-user, 2017-2031
11.4.1. Hospitals
11.4.2. Cancer & Radiation Therapy Centers
11.4.3. Others (specialty clinics)
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Cancer Type
11.6.2. By Treatment Type
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Lung Cancer Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Cancer Type, 2017-2031
12.2.1. NSCLC
12.2.2. SCLC
12.3. Market Value Forecast, by Treatment Type, 2017-2031
12.3.1. Surgery
12.3.2. Radiation Therapy
12.3.3. Targeted Therapy
12.3.4. Immunotherapy
12.3.5. Chemotherapy
12.3.6. Others (palliative care)
12.4. Market Value Forecast, by End-user, 2017-2031
12.4.1. Hospitals
12.4.2. Cancer & Radiation Therapy Centers
12.4.3. Others (specialty clinics)
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Cancer Type
12.6.2. By Treatment Type
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Lung Cancer Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Cancer Type, 2017-2031
13.2.1. NSCLC
13.2.2. SCLC
13.3. Market Value Forecast, by Treatment Type, 2017-2031
13.3.1. Surgery
13.3.2. Radiation Therapy
13.3.3. Targeted Therapy
13.3.4. Immunotherapy
13.3.5. Chemotherapy
13.3.6. Others (palliative care)
13.4. Market Value Forecast, by End-user, 2017-2031
13.4.1. Hospitals
13.4.2. Cancer & Radiation Therapy Centers
13.4.3. Others (specialty clinics)
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Cancer Type
13.6.2. By Treatment Type
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Lung Cancer Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Cancer Type, 2017-2031
14.2.1. NSCLC
14.2.2. SCLC
14.3. Market Value Forecast, by Treatment Type, 2017-2031
14.3.1. Surgery
14.3.2. Radiation Therapy
14.3.3. Targeted Therapy
14.3.4. Immunotherapy
14.3.5. Chemotherapy
14.3.6. Others (palliative care)
14.4. Market Value Forecast, by End-user, 2017-2031
14.4.1. Hospitals
14.4.2. Cancer & Radiation Therapy Centers
14.4.3. Others (specialty clinics)
14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Cancer Type
14.6.2. By Treatment Type
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Pfizer
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Cancer Type Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. AstraZeneca
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Cancer Type Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Merck (MSD)
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Cancer Type Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Bristol-Myers Squibb
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Cancer Type Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Eli Lilly and Company
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Cancer Type Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.6. Boehringer Ingelheim
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Cancer Type Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.7. Novartis
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Cancer Type Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.8. Merck KGaA (EMD Serono)
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Cancer Type Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.9. AbbVie
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Cancer Type Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.10. Takeda
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Cancer Type Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.11. Astellas Pharma
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Cancer Type Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.12. F. Hoffmann-La Roche
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Cancer Type Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.13. GlaxoSmithKline
15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.13.2. Cancer Type Portfolio
15.3.13.3. Financial Overview
15.3.13.4. SWOT Analysis
15.3.14. Johnson & Johnson
15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.14.2. Cancer Type Portfolio
15.3.14.3. Financial Overview
15.3.14.4. SWOT Analysis
15.3.15. Sanofi
15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.15.2. Cancer Type Portfolio
15.3.15.3. Financial Overview
15.3.15.4. SWOT Analysis
15.3.16. Amgen
15.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.16.2. Cancer Type Portfolio
15.3.16.3. Financial Overview
15.3.16.4. SWOT Analysis
List of Tables
Table 01: Global Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 02: Global Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
Table 03: Global Lung Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 04: Global Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 05: North America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 06: North America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 07: North America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
Table 08: North America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 09: Europe Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 10: Europe Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 11: Europe Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
Table 12: Europe Lung Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 13: Asia Pacific Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Asia Pacific Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 15: Asia Pacific Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
Table 16: Asia Pacific Lung Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 17: Latin America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 18: Latin America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 19: Latin America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
Table 20: Latin America Lung Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 21: Middle East & Africa Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Middle East & Africa Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 23: Middle East & Africa Lung Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
Table 24: Middle East & Africa Lung Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017-2031
List of Figures
Figure 01: Global Lung Cancer Treatment Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Global Lung Cancer Treatment Market Value Share, by Cancer Type (2021)
Figure 03: Global Lung Cancer Treatment Market Value Share, by End-user (2021)
Figure 04: Global Lung Cancer Treatment Market Value Share, by Treatment Type (2021)
Figure 05: Global Lung Cancer Treatment Market Value Share, by Region (2021)
Figure 06: Global Lung Cancer Treatment Market Value Share Analysis, by Cancer Type, 2021 and 2031
Figure 07: Global Lung Cancer Treatment Market Revenue (US$ Mn), by NSCLC, 2017-2031
Figure 08: Global Lung Cancer Treatment Market Revenue (US$ Mn), by SCLC, 2017-2031
Figure 09: Global Lung Cancer Treatment Market Attractiveness Analysis, by Cancer Type, 2022-2031
Figure 10: Global Lung Cancer Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 11: Global Lung Cancer Treatment Market Revenue (US$ Mn), by Surgery, 2017-2031
Figure 12: Global Lung Cancer Treatment Market Revenue (US$ Mn), by Radiation Therapy, 2017-2031
Figure 13: Global Lung Cancer Treatment Market Revenue (US$ Mn), by Others, 2017-2031
Figure 14: Global Lung Cancer Treatment Market Attractiveness Analysis, by Treatment Type, 2022-2031
Figure 15: Global Lung Cancer Treatment Market Value Share Analysis, by End-user, 2021 and 2031
Figure 16: Global Lung Cancer Treatment Market Revenue (US$ Mn), by Hospitals, 2017-2031
Figure 17: Global Lung Cancer Treatment Market Revenue (US$ Mn), by Cancer & Radiation Therapy Centers, 2017-2031
Figure 18: Global Lung Cancer Treatment Market Revenue (US$ Mn), by Others (specialty clinics), 2017-2031
Figure 19: Global Lung Cancer Treatment Market Attractiveness Analysis, by End-user, 2022-2031
Figure 20: Global Lung Cancer Treatment Market Value Share Analysis, by Region, 2021 and 2031
Figure 21: Global Lung Cancer Treatment Market Attractiveness Analysis, by Region, 2022-2031
Figure 22: North America Lung Cancer Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 23: North America Lung Cancer Treatment Market Value Share (%), by Country, 2021 and 2031
Figure 24: North America Lung Cancer Treatment Market Attractiveness Analysis, by Country, 2022-2031
Figure 25: North America Lung Cancer Treatment Market Value Share Analysis, by Cancer Type, 2021 and 2031
Figure 26: North America Lung Cancer Treatment Market Attractiveness Analysis, by Cancer Type, 2022-2031
Figure 27: North America Lung Cancer Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 28: North America Lung Cancer Treatment Market Attractiveness Analysis, by Treatment Type, 2022-2031
Figure 29: North America Lung Cancer Treatment Market Value Share Analysis, by End-user, 2021 and 2031
Figure 30: North America Lung Cancer Treatment Market Attractiveness Analysis, by End-user, 2022-2031
Figure 31: Europe Lung Cancer Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 32: Europe Lung Cancer Treatment Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 33: Europe Lung Cancer Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 34: Europe Lung Cancer Treatment Market Value Share Analysis, by Cancer Type, 2021 and 2031
Figure 35: Europe Lung Cancer Treatment Market Attractiveness Analysis, by Cancer Type, 2022-2031
Figure 36: Europe Lung Cancer Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 37: Europe Lung Cancer Treatment Market Attractiveness Analysis, by Treatment Type, 2022-2031
Figure 38: Europe Lung Cancer Treatment Market Value Share Analysis, by End-user, 2021 and 2031
Figure 39: Europe Lung Cancer Treatment Market Attractiveness Analysis, by End-user, 2022-2031
Figure 40: Asia Pacific Lung Cancer Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 41: Asia Pacific Lung Cancer Treatment Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 42: Asia Pacific Lung Cancer Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 43: Asia Pacific Lung Cancer Treatment Market Value Share Analysis, by Cancer Type, 2021 and 2031
Figure 44: Asia Pacific Lung Cancer Treatment Market Attractiveness Analysis, by Cancer Type, 2022-2031
Figure 45: Asia Pacific Lung Cancer Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 46: Asia Pacific Lung Cancer Treatment Market Attractiveness Analysis, by Treatment Type, 2022-2031
Figure 47: Asia Pacific Lung Cancer Treatment Market Value Share Analysis, by End-user, 2021 and 2031
Figure 48: Asia Pacific Lung Cancer Treatment Market Attractiveness Analysis, by End-user, 2022-2031
Figure 49: Latin America Lung Cancer Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 50: Latin America Lung Cancer Treatment Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 51: Latin America Lung Cancer Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 52: Latin America Lung Cancer Treatment Market Value Share Analysis, by Cancer Type, 2021 and 2031
Figure 53: Latin America Lung Cancer Treatment Market Attractiveness Analysis, by Cancer Type, 2022-2031
Figure 54: Latin America Lung Cancer Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 55: Latin America Lung Cancer Treatment Market Attractiveness Analysis, by Treatment Type, 2022-2031
Figure 56: Latin America Lung Cancer Treatment Market Value Share Analysis, by End-user, 2021 and 2031
Figure 57: Latin America Lung Cancer Treatment Market Attractiveness Analysis, by End-user, 2022-2031
Figure 58: Middle East & Africa Lung Cancer Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 59: Middle East & Africa Lung Cancer Treatment Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 60: Middle East & Africa Lung Cancer Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 61: Middle East & Africa Lung Cancer Treatment Market Value Share Analysis, by Cancer Type, 2021 and 2031
Figure 62: Middle East & Africa Lung Cancer Treatment Market Attractiveness Analysis, by Cancer Type, 2022-2031
Figure 63: Middle East & Africa Lung Cancer Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031
Figure 64: Middle East & Africa Lung Cancer Treatment Market Attractiveness Analysis, by Treatment Type, 2022-2031
Figure 65: Middle East & Africa Lung Cancer Treatment Market Value Share Analysis, by End-user, 2021 and 2031
Figure 66: Middle East & Africa Lung Cancer Treatment Market Attractiveness Analysis, by End-user, 2022-2031
Figure 67: Global Lung Cancer Treatment Market Share Analysis, by Company, 2021
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security